CABG or PCI in Patients With Ischemic Cardiomyopathy

Who May Qualify: 1. Age ≥18 years. 2. Symptomatic HF defined as NYHA HF class II-IV within 1 month of enrolment 3. LVEF ≤ 40% quantified by either echocardiography or gated SPECT ventriculography, or magnetic resonance (MR) or any other recognized assessment of LVEF 4. Meaningful amount of myocardium at risk because of CAD (BCIS myocardial jeopardy score ≥ 6 on a recent (\> 6 months) coronary angiogram); 5. Heart team believes that a meaningful revascularization can be achieved by both PCI or CABG, with complete revascularization defined as residual ischemia in \<10% of the left ventricle 6. Heart team agrees that guideline directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible, in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization 7. Written willing to sign a consent form obtained Who Should NOT Join This Trial: 1. Previous randomization in the study 2. Decompensated heart failure requiring inotropic /adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ventricular assist device therapy less than 48 hours prior to randomization 3. Recent (\<1 month) type 1 myocardial infarction 4. Recent PCI (\<3 months) 5. Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) requiring surgical repair/replacement 6. Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy 7. Expected survival less than 3 years due to non-cardiac illness 8. Circumstances likely to lead to poor treatment compliance 9. Individuals for whom record in public health databases is not accessible (non-eligibility to public health system, parallel healthcare systems ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.